Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
24
KTTA Quote, Financials, Valuation and Earnings
Last price:
$0.74
Seasonality move
:
-5.84%
Day range:
$0.71 - $0.78
52-week range:
$0.28 - $3.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.44x
Volume:
327.2K
Avg. volume:
217.6K
1-year change:
-66.12%
Market cap:
$5.4M
Revenue:
--
EPS (TTM):
-$5.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
-- | -$0.18 | -- | -92.51% | $3.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$298.6M | $0.20 | 13.44% | 28.72% | $31.21 |
|
BEAT
HeartBeam, Inc.
|
$266.7K | -- | -- | -- | $4.63 |
|
ENVB
Enveric Biosciences, Inc.
|
-- | -$0.55 | -- | -60% | $10.00 |
|
ONMD
OneMedNet Corp.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
$0.73 | $3.00 | $5.4M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
BEAT
HeartBeam, Inc.
|
$1.43 | $4.63 | $49.3M | -- | $0.00 | 0% | -- |
|
ENVB
Enveric Biosciences, Inc.
|
$2.37 | $10.00 | $1.2M | -- | $0.00 | 0% | 0.02x |
|
ONMD
OneMedNet Corp.
|
$0.73 | -- | $37.2M | -- | $0.00 | 0% | 56.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
0.32% | -3.621 | 0.72% | 3.07x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
BEAT
HeartBeam, Inc.
|
-- | -1.677 | -- | 0.75x |
|
ENVB
Enveric Biosciences, Inc.
|
-- | 1.271 | -- | 4.15x |
|
ONMD
OneMedNet Corp.
|
-10.93% | 7.553 | 0.72% | 0.27x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KTTA
Pasithea Therapeutics Corp.
|
-$181.5K | -$3.1M | -91.9% | -92.48% | -- | -$2.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
BEAT
HeartBeam, Inc.
|
-$8K | -$5.3M | -555.14% | -555.14% | -- | -$3.2M |
|
ENVB
Enveric Biosciences, Inc.
|
-$40.4K | -$1.9M | -322.21% | -322.21% | -- | -$2.1M |
|
ONMD
OneMedNet Corp.
|
-$232K | -$2.2M | -- | -- | -1262.71% | -$1.6M |
Pasithea Therapeutics Corp. vs. Competitors
-
Which has Higher Returns KTTA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of 25.76%. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About KTTA or ACAD?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 313.79%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that Pasithea Therapeutics Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Pasithea Therapeutics Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is KTTA or ACAD More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock KTTA or ACAD?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ACAD?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Pasithea Therapeutics Corp.'s net income of -$3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns KTTA or BEAT?
HeartBeam, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of --. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat HeartBeam, Inc.'s return on equity of -555.14%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M BEATHeartBeam, Inc.-- -$0.15 $406K -
What do Analysts Say About KTTA or BEAT?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 313.79%. On the other hand HeartBeam, Inc. has an analysts' consensus of $4.63 which suggests that it could grow by 223.43%. Given that Pasithea Therapeutics Corp. has higher upside potential than HeartBeam, Inc., analysts believe Pasithea Therapeutics Corp. is more attractive than HeartBeam, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 BEATHeartBeam, Inc.2 1 0 -
Is KTTA or BEAT More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HeartBeam, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KTTA or BEAT?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HeartBeam, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. HeartBeam, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or BEAT?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than HeartBeam, Inc. quarterly revenues of --. Pasithea Therapeutics Corp.'s net income of -$3M is higher than HeartBeam, Inc.'s net income of -$5.3M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while HeartBeam, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus -- for HeartBeam, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M BEATHeartBeam, Inc.-- -- -- -$5.3M
-
Which has Higher Returns KTTA or ENVB?
Enveric Biosciences, Inc. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of --. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat Enveric Biosciences, Inc.'s return on equity of -322.21%.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M -
What do Analysts Say About KTTA or ENVB?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 313.79%. On the other hand Enveric Biosciences, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 4963.29%. Given that Enveric Biosciences, Inc. has higher upside potential than Pasithea Therapeutics Corp., analysts believe Enveric Biosciences, Inc. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ENVBEnveric Biosciences, Inc.0 0 0 -
Is KTTA or ENVB More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enveric Biosciences, Inc. has a beta of 0.298, suggesting its less volatile than the S&P 500 by 70.169%.
-
Which is a Better Dividend Stock KTTA or ENVB?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enveric Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. Enveric Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ENVB?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than Enveric Biosciences, Inc. quarterly revenues of --. Pasithea Therapeutics Corp.'s net income of -$3M is lower than Enveric Biosciences, Inc.'s net income of -$1.9M. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while Enveric Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 0.02x for Enveric Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M
-
Which has Higher Returns KTTA or ONMD?
OneMedNet Corp. has a net margin of -- compared to Pasithea Therapeutics Corp.'s net margin of -418.64%. Pasithea Therapeutics Corp.'s return on equity of -92.48% beat OneMedNet Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M ONMDOneMedNet Corp.-131.07% -$0.01 -$3.6M -
What do Analysts Say About KTTA or ONMD?
Pasithea Therapeutics Corp. has a consensus price target of $3.00, signalling upside risk potential of 313.79%. On the other hand OneMedNet Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pasithea Therapeutics Corp. has higher upside potential than OneMedNet Corp., analysts believe Pasithea Therapeutics Corp. is more attractive than OneMedNet Corp..
Company Buy Ratings Hold Ratings Sell Ratings KTTAPasithea Therapeutics Corp.1 0 0 ONMDOneMedNet Corp.0 0 0 -
Is KTTA or ONMD More Risky?
Pasithea Therapeutics Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OneMedNet Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KTTA or ONMD?
Pasithea Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OneMedNet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pasithea Therapeutics Corp. pays -- of its earnings as a dividend. OneMedNet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KTTA or ONMD?
Pasithea Therapeutics Corp. quarterly revenues are --, which are smaller than OneMedNet Corp. quarterly revenues of $177K. Pasithea Therapeutics Corp.'s net income of -$3M is lower than OneMedNet Corp.'s net income of -$741K. Notably, Pasithea Therapeutics Corp.'s price-to-earnings ratio is -- while OneMedNet Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pasithea Therapeutics Corp. is -- versus 56.46x for OneMedNet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KTTAPasithea Therapeutics Corp.-- -- -- -$3M ONMDOneMedNet Corp.56.46x -- $177K -$741K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
